Quantitative analysis of proteomic profiling in constipation colon biopsies

CURRENT STATUS: UNDER REVIEW

Clinical Proteomics  ■ BMC

Chen Ye
Shanghai Tenth People's Hospital

445758559@qq.com Corresponding Author
ORCID: https://orcid.org/0000-0002-9185-8242

Qiyi Chen
Shanghai Tenth People's Hospital

Di Zhao
Shanghai Tenth People's Hospital

Hongliang Tian
Shanghai Tenth People's Hospital

Xueying Zhang
Shanghai Tenth People's Hospital

Zhiliang Lin
Shanghai Tenth People's Hospital

Bo Yang
Shanghai Tenth People's Hospital

Ning Li
Shanghai Tenth People's Hospital

DOI:
10.21203/rs.3.rs-22005/v1

SUBJECT AREAS
Medical Informatics

KEYWORDS
constipation, proteomics, cytochrome P450
Abstract
Background Chronic constipation is a common disease and between 2% and 27% of people are suffering from it in the world. Rare studies explore the diversity of genetic polymorphisms and cell metabolisms in constipation. This study provided a first analysis of constipation-related proteomic data.

Methods To help elucidate the potential mechanisms responsible for constipation, proteomic profiling of human colon biopsy specimens was performed. Dysregulated proteins in disease tissues compared with normal tissues were characterized from the expression profiles by Liquid chromatography–mass spectrometry and Tandem Mass Tag proteomic methodology and further subjected to pathway analysis to identify altered biological processes and signaling pathways.

Results A total of 5,208 proteins were identified, of which 4,522 had quantitative information. All the differentially expressed proteins displayed fold change greater than 1.3 were considered as dysregulated. Specifically, 42 proteins were up-regulated and 23 proteins were down-regulated in constipation samples. Bioinformatics analysis showed that most of the differentially expressed proteins were involved in the cellular process, single-organism process, metabolic process, biological regulation and response to stimulus. Pathway analysis of dysregulated proteins in constipation showed that the up-regulated proteins mainly participated in drug metabolism-cytochrome P450.

Conclusions The TMT method followed by mass spectrometric analysis was applied to study the biopsy proteomic profiling alterations in constipation patients. Our results clearly proved that different protein profiles and signaling pathways were involved in constipation patients.

Background
Chronic constipation is a common disease and between 2% and 27% of people are suffering from it in the world\(^1\)-\(^3\). It is defined as bowel movements fewer than three times per week for at least three months out of the recent 12 months and having symptoms such as difficulty passing stool, hard stools, abdominal bloating, feelings of incomplete stool passage and pain\(^1\). Many factors cause constipation. Abnormal innervation of the bowel myopathy, abnormal muscle contractions in the rectum, diet, medication, and psychosocial stress may lead to constipation, megacolon and stercoral
obstruction. Although current therapies like laxatives and fecal microbiota transplantation have improved the clinical management of constipation, a number of patients have limited benefit and need surgical treatment. The clinical heterogeneity and therapeutic response suggest that the underlying disease-inducing mechanisms might differ between affected patients. The increasing evidence reveals the genomic features and signaling pathways of colorectum, however rare studies explore the diversity of genetic polymorphisms and cell metabolisms in constipation. Proteomic profiling in constipation in colon may be translated into novel and effective treatments. The etiology of constipation remains a conundrum. Transcriptomic and Proteomic Profiling in other bowel diseases, such as inflammatory bowel disease, colorectal cancer, have made considerable achievements, giving our understanding of the pathogenesis. Understanding of the proteomics involved in constipation allows us to further understand the pathogenesis. The sequencing technology have succeeded to expanded our vision nowadays. As protein plays a fundamental role in coupling genotypes to phenotypes, measurement of protein abundance is important. Traditional proteomics were limited to serum and blood samples as clinical colon samples are more difficult to acquire. Liquid chromatography-mass spectrometry (LC-MS) and Tandem Mass Tag (TMT) proteomic methodology were optimized to handle large tissue samples. It is reported that TMT quantitative proteomics were used to screen for diagnostic and prognostic protein biomarkers. Hereby, we examined the differential expression of proteins in constipation colon biopsies and non-constipation ones by using TMT-based quantitative proteomics. Our study that provided a first analysis of constipation-related proteomic data may provide a more essential understanding of the information flow from protein to phenotype.

Methods
Sample collection
The study enrolled 20 inpatients in the Tenth People’s Hospital of Tongji University. The patients (n = 12) who had refractory mixed constipation or constipation with megacolon and ileus received subtotal colectomy combined with modified Duhamel procedure and those (n = 8) who had left colon cancer
received left hemicolecotomy. After operation, fresh colon biopsies were taken from left colon solid specimen, excluding cancer or ulcer tissue. The most homogeneous samples were selected for proteomic analysis. All biopsy samples were collected and processed by standard operating procedures to reduce deviation.

Protein preparation and TMT labeling
The biopsy samples which were taken from –80 °C were grinded by liquid nitrogen into cell powder and transferred to a 5-mL centrifuge tube. Then, 4 volumes of lysis buffer (8M urea, 1% Protease Inhibitor Cocktail) was added to the cell powder, followed by sonication three times on ice using a high intensity ultrasonic processor (Scientz). After that, The remaining debris was removed by centrifugation at 12,000 g at 4 °C for 10 min. Finally, the supernatant was collected and the protein concentration was determined with BCA kit according to the manufacturer’s instructions.

The protein solution was reduced with 5 mM dithiothreitol for 30 min at 56 °C and alkylated with 11 mM iodoacetamide for 15 min at indoor temperature in darkness for digestion. The protein samples were then diluted by adding 100 mM TEAB to urea concentration less than 2M. Trypsin was then added at 1:50 trypsin-to-protein mass ratio for the first digestion overnight and 1:100 trypsin-to-protein mass ratio for a second 4 h-digestion. After that, peptides were desalted by Strata X C18 SPE column (Phenomenex) and vacuum-dried. Peptides were reconstituted in 0.5M TEAB and processed according to the manufacturer’s protocol for TMT kit. Finally, The peptide mixtures were incubated for 2 h at indoor temperature and then pooled, desalted and dried by vacuum centrifugation.

Hplc Fractionation And Lc-ms/ms Analysis
Tryptic peptides were fractionated into fractions by high pH reverse-phase HPLC using Agilent 300Extend C18 column (5 µm particles, 4.6 mm ID, 250 mm length). Firstly, the peptides were separated with a gradient of 8–32% acetonitrile (pH 9.0) over 60 min into 60 fractions. Secondly, they were combined into 18 fractions and then dried by vacuum centrifuging.

The tryptic peptides were dissolved in solvent A (0.1% formic acid) and then separated by EASY-nLC 1000 UPLC system. Solvent A was an aqueous solution which contained 0.1% formic acid and 2% acetonitrile, while solvent B was an aqueous solution containing 0.1% formic acid and 90%
acetonitrile. The gradient setting was: 0 ~ 40 min, 6%-18% B; 40 ~ 52 min, 18%-28% B; 52–56 min, 28%-80% B; 56 ~ 60 min, 80% B, all at a constant flow rate of 300 nL/min.

The peptides were subjected to NSI source followed by tandem mass spectrometry in Orbitrap Fusion™ Lumos coupled online to the UPLC. The electrospray voltage applied was 2.4 kV. The m/z scan range was 350 to 1550 for full MS scan and intact peptides were detected in the Orbitrap at a resolution of 60,000. Then, the peptides were selected for MS/MS at a fixed starting point of 100 m/z and the fragments were detected in the Orbitrap at a resolution of 30,000. A data-dependent acquisition procedure was used in the data acquisition mode. After the MS scan, the top 10 peptide parent ions with the highest signal strength were successively selected to enter the HCD collision cell for fragmentation in 32% of the fragmentation energy, and were then tested by the MS/MS scan. In order to improve the effective utilization of mass spectrum, automatic gain control was set to 5E4, signal threshold was set to 20000 ions/s, maximum injection time was set to 100 ms and dynamic exclusion time of tandem mass spectra scan was set to 30 s to avoid repeated scanning of parent ions.

Data analysis
The resulting MS/MS data were processed by using Maxquant search engine (v.1.5.2.8). The database was SwissProt Human (20317 sequences) and the inverse library was added to calculate the false positive rate caused by random matching. And the common contamination library was added in the database to eliminate the influence of contaminated proteins in the identification results. Trypsin/P was specified as cleavage enzyme which allowed up to 2 missing cleavages. The minimum length of the peptide was set as 7 amino acid residues. The maximum modification number of the peptide was set to 5. The mass tolerance for precursor ions was set as 20 ppm in First search and 5 ppm in Main search, and the mass tolerance for fragment ions was set as 0.02 Da. Carbamidomethyl on Cys was specified as fixed modification and oxidation on Met and acetylation on protein N terminal were specified as variable modifications. The quantitative method was set as TMT-10plex and the FDR for protein identification and PSM identification was adjusted to 1%

The quality control test results of MS data were showed in Fig. 1. Firstly, mass errors of all identified
peptides were detected (Fig. 1.A). The quality error takes 0 as the axis and concentrates on the range below 10 PPM, indicating that the quality error meets the requirements. Secondly, the length of most of the peptides was distributed between 8–20 amino acid residues (Fig. 1.B), which was in line with the rules of trypsin digestion of peptides, demonstrating that the sample preparation reached the standard.

**Bioinformatics Analysis**

Gene Ontology (GO) annotation proteome came from the UniProt-GOA database (www.ebi.ac.uk/GOA/). Firstly, converting identified protein ID to UniProt ID and then mapping to GO IDs by protein ID. If some identified proteins were not annotated by UniProt-GOA database, the InterProScan soft would be used to annotate protein’s GO function by protein sequence alignment method. Then, the proteins were classified by GO annotation based on three categories: biological process, molecular function and cellular component. A two-tailed Fisher’s exact test was used to test the enrichment of the proteins which were differentially expressed for each category. The GO with a p value < 0.05 was considered significantly different.

Identified proteins domain functional description were annotated by InterProScan (http://www.ebi.ac.uk/interpro/) based on protein sequence alignment method. InterPro is a database that integrates diverse information about protein families, domains and functional sites. For each category proteins, the two-tailed Fisher’s exact test was also employed to test the enrichment of the differentially expressed protein against all identified proteins. Protein domains with a p value < 0.05 were significantly different.

Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used to annotate protein pathway. KEGG Pathways mainly include Metabolism, Genetic Information Processing, Environmental Information Processing, Cellular Processes, Rat Diseases and Drug development etc. KEGG database was used to identify enriched pathways by the two-tailed Fisher’s exact test and p value was also < 0.05. These pathways were classified into hierarchical categories according to the KEGG website. Subcellular localization was used to annotate elements in the cell mapped to proteins in eukaryotic tissue cells. It was depended on the membrane structures. The main subcellular locations of
Eukaryotic cells include extracellular, cytoplasmic, nuclear, mitochondrial, golgi, endoplasmic reticulum, peroxidase bodies, vacuoles, cytoskeleton, cytoplasm, nuclear matrix, and ribosomes etc. Based on this, we used the software wolfpsort to predict the subcellular localization to annotate the subcellular localization of the submitted proteins and CELLO software to predict the subcellular structure of prokaryotes.

Further hierarchical clustering was based on different protein functional classifications, including GO, Domain and KEGG. All the categories were collated after enrichment along with their p values, and then those categories which were at least enriched in one of the clusters with p value < 0.05 were filtered. This filtered p value matrix was transformed by the function $x = -\log_{10}(p)$ value. Finally, those x values were z-transformed for each functional category. The z scores were then clustered by one-way hierarchical clustering (Euclidean distance, average linkage clustering) in Genesis. Cluster membership were visualized by a heat map using the “heatmap.2” function from the “gplots” R-package.

Statistical analysis
The differences between two groups were analyzed with Student’s t test. P < 0.05 was statistically considered different. Statistical analysis was performed by the Statistical Program for Social Sciences (SPSS) software 22.0 (SPSS Inc., Chicago, IL, USA).

Results
Transcriptomic Profiling of the study population
Human colon biopsies (n = 20) including 12 samples from constipation and 8 samples from non-constipation (Table 1). All selected patients had similar gender and ages. Besides, there were no significant differences in disease duration or concomitant ileus between two groups.

| Characters          | constipation group (n = 12) | non-constipation group (n = 8) | P value |
|---------------------|----------------------------|--------------------------------|---------|
| Gender (M/F)        | 3/9                        | 3/5                            | 0.550   |
| Age (years)         | 45.14 ± 12.21              | 52.67 ± 17.62                  | 0.451   |
| Disease duration (years) | 15.29 ± 12.87          | 0.83 ± 0.29                    | 0.097   |
| Concomitant ileus   | 58.3%                      | 37.5%                          | 0.361   |

Identification Of Biopsy Proteins
In this study, a total of 5,208 proteins were identified, of which 4,522 had quantitative information. All
the differentially expressed proteins which were displayed fold change greater than 1.3 were considered dysregulated. As a result, 42 proteins were up-regulated and 23 proteins were down-regulated in constipation samples.

The box-plot was plotted by the deviation standard coefficient calculated by repeated experimental values of each group of samples, indicating the dispersion and fluctuation degree of repeated data. The quantitative results of biological or technical duplicates were statistically consistent.

Functional Classification And Enrichment Analysis Of Differentially Expressed Proteins

In order to thoroughly understand the identified and quantified proteins in the data, functions and characteristics of those proteins were annotated in detail from the aspects of subcellular localization, GO, protein domain and KEGG pathway. For the annotation of all identified proteins and the screening of differentially expressed proteins, enrichment analysis of GO, KEGG, domain and other functional annotation types were conducted to detect whether the differentially expressed proteins have a significant enrichment trend in some functional types.

Wolfpsort software was used to predict and classify the subcellular structures of differentially expressed proteins (Fig. 1). 33% of up-regulated proteins were annotated as belonging to cytoplasm, while more than 30% of down-regulated proteins were extracellular and nucleus.

The distribution of the quantified proteins in the GO secondary annotation was statistically analyzed. Biological process, cellular component and molecular function explained the biological role of proteins from different perspectives. Using GO, glucose 1-phosphate metabolic process and response to toxic substance in biological process, lyase activity and carbonate dehydratase activity in molecular function, organellar and mitochondrial small ribosomal subunit in cellular component were significantly enriched in up-regulated proteins (Fig. 2A), while negative regulation and regulation of cell-substrate adhesion in biological process, extracellular matrix structural constituent and platelet-derived growth factor binding in molecular function, proteinaceous extracellular matrix and extracellular matrix in cellular component were significantly enriched in down-regulated proteins (Fig. 2B).
KEGG pathways include metabolism, genetic information processing, environmental information processing, cell processes, human diseases, drug development, etc. KEGG generated networks that demonstrated significant hubs of dysregulation in constipation patients in the work (Fig. 3). The regulation of KEGG pathway obtained by enrichment analysis. The up-regulated proteins mainly participated in drug metabolism-cytochrome P450, nitrogen metabolism, galactose metabolism, chemical carcinogenesis, metabolism of xenobiotics by cytochrome P450, amino sugar and nucleotide sugar metabolism, glutathione metabolism, platinum drug resistance and drug metabolism-other enzymes, while the down-regulated proteins took part in protein digestion and absorption, AGE-RAGE signaling pathway in diabetic complications, amoebiasis, relaxin signaling pathway and platelet activation. Of these categories, drug metabolism-cytochrome P450, nitrogen metabolism and protein digestion and absorption were the highest scoring KEGG network (Fig. 4). Constipation might have unique molecular mechanisms and molecular characteristics.

Protein domain refers to some components that occur repeatedly in different protein molecules and have similar sequences, structures and functions. It is the unit of protein evolution. The domain length is usually between 25 amino acids and 500 amino acids. Alpha carbonic anhydrase and S-adenosyl-L-methionine-dependent methyltransferase were in up-regulated proteins, and "VWFC domain, fibrillar collagen, C-terminal, "Zinc finger, LIM-type, Butyrophylin-like, SPRY domain, B30.2/SPRY domain, Immunoglobulin subtype, Immunoglobulin-like fold, leucine-rich repeat domain, L domain-like, Immunoglobulin-like domain, C2 domain and concanavalin A-like lectin/glucanase domain were in down-regulated proteins. Alpha carbonic anhydrase, "VWFC domain and fibrillar collagen, C-terminal were statistically significant. Unique protein domains were appeared in constipation.

Clustering Analysis Of Dysregulated Proteins
Differentially expressed proteins were divided into four parts according to their differentially expressed multiples, called Q1 to Q4: Q1 (0 < Ratio ≤ 1/1.3), Q2 (1/1.3 < Ratio ≤ 1/1.2), Q3 (1.2 < Ratio ≤ 1.3) and Q4 (Ratio > 1.3). GO classification, KEGG and protein domain enrichment were conducted for each Q group, and cluster analysis was conducted to find the correlation of protein function with different differentially expressed multiples. In results, Q1 had 23 proteins, Q2 had 14
proteins, Q3 had 22 proteins and Q4 had 42 proteins. According to Fisher's exact test, p value which was obtained from enrichment analysis used clustering method to gather the relevant functions in different groups together and draw a heatmap. The heatmap represents the enrichment test results of different groups horizontally, and the longitudinal description of GO, KEGG pathway, protein domain. The color blocks corresponding to the differentially expressed proteins and functional descriptions in different groups indicated the degree of enrichment. Red indicated strong enrichment and blue represented weak enrichment. For example, response to transforming growth factor beta in Q1 and phosphorylation in Q4 were strong enrichment in biological process of GO terms, and AGE-RAGE signaling pathway in diabetic complications in Q1 and metabolism of xenobiotics by cytochrome P450 in Q4 were strong enrichment in KEGG pathway (Fig. 5,6).

Discussion
Chronic constipation is getting more attention worldwide with the rising of study in brain-gut axis and fecal microbiota transplantation\textsuperscript{14-16}. Severe constipation can severely affect qualities of life, even making people having mental diseases\textsuperscript{16-18}. Changes in gut were related to hormone and brain, and the environment of gut might be the causal, while little is known about the specific mechanisms and the differences in different biological pathways. It is the first time to report characters of constipation patients at the proteome level. These data represented in the study, not only confirm constipation patients might have potential mechanisms, but also provide new information regarding constipation patients, which will need further investigations.

In the study, a quantitative proteomic analysis of colon biopsy samples from constipation patients and non-constipation controls was carried out by TMT labeling, HPLC and LC–MS/MS to quantify the specific changes in biopsy proteome of constipation patients. There were 4522 proteins quantified, of which 65 proteins were differentially expressed by > 1.3-or < 0.77-fold. Bioinformatics analysis showed that the differentially expressed proteins were mostly involved in the cellular process, single-organism process, metabolic process, biological regulation and response to stimulus, which mainly reflected abnormal functions of immunity. By contrast, constipation patients have a higher risk of
inflammatory disorders and poorer clinical outcomes. Constipation patients with megacolon or ileus have a higher incidence of complications after operation, such as parenteral fistula and sepsis. Furthermore, this phenomenon was further supported by the obviously altered drug metabolism-cytochrome P450 pathway in constipation patients, as cytochrome P450-mediated metabolism of arachidonic acid regulates inflammation in hepatic and extrahepatic tissue. Acute inflammatory stimuli suppress cytochrome P450 expression via a pretranslational mechanism, decreasing xenobiotic metabolism and clearance in preclinical models and humans. A significant discovery from this work was that many proteins related to the drug metabolism-cytochrome P450 pathway may be used as novel biological markers of constipation patients. The human CYP supergene family consists of 57 genes and only 12 of the encoded enzymes are responsible for more than 75% of all phase 1 drug oxidation reactions. In addition to being necessary structural components, cytochrome P450 molecules also play critical roles in the control of key metabolic events. They take part in metabolism of exogenous substances, such as drugs, alcohol, antioxidants, organic solvents, anesthetics, dyes, environmental pollutants and chemicals, may leading to toxic or carcinogenic metabolites. Besides, cytochrome P450 molecules play an important role in oxidation, peroxidation and reduction of endogenous physiological compounds, such as steroids, bile acids, fatty acids, prostaglandins, biogenic ammonia and retinoids. The number of samples was small and it was necessary to elucidate and generalize mechanisms by a larger size of samples and some significantly changed proteins.

Mechanisms of constipation are related to dysbacteriosis. It is unknown whether bacteria have an effect on protein profiling of host. Proteome study may help explore the relationship between host genes, microbiota gene and the target of acting site. Target protein modification site should be selected from differently expressed protein. Priority should be given to the location of the modification site in the important function of target protein domains, other protein interaction domain and the activity of enzyme protein catalytic center key functions such as regulatory regions.
proteins need to be translated into laboratory technique or medicine, enabling new advances in biology, diagnostics and therapeutics. In this study, patients who had refractory mixed constipation or constipation with megacolon and ileus, need to receive operations\textsuperscript{3}. Nevertheless, many constipation patients can achieve relief or cure by probiotics, prebiotics, laxatives or fecal microbiota transplantation\textsuperscript{2,14}. Different severity of constipation has different clinical prognosis and the protein profiling might have specific range, which facilitate further verification.

Conclusion
The TMT labeling and LC-MS/MS followed by MS analysis were applied to study the biopsy proteomic profiling alterations in constipation patients. This study proved that constipations had specific protein profiles and certain signaling pathways, related to inflammation reactions. The potential application proteins as biomarkers for distinguishing constipation individuals need further study.

Declarations
Ethics approval and consent to participate: Written informed consent was obtained from individual participants.

Consent for publication: Written informed consent for publication was obtained from all participants.

Availability of data and material: All relevant data are within the paper and its Supporting Information files.

Competing Interests: All authors declared no competing interests for this work.

Funding: This study was supported by the National Nature Science Foundation of China (no.81670493).

Authors’ contributions: Ye, Chen and Li analyzed and interpreted the patient data and were major contributors in writing the manuscript. Tian, Lin, Zhang, Yang and Zhao performed the histological examination of the colons.

Acknowledgements: We appreciated for the manuscript.

References
1. Treatments for Constipation: A Review of Systematic Reviews. Ottawa (ON)2014.
2. Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nature reviews Disease
primers. 2017;3:17095.

3. Jiang J, Chen Q, Feng X, et al. [Therapeutic effect and long-term follow-up of the Jinling procedure for refractory constipation: a series of 1 100 cases]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2016;54(1):13–20.

4. Hill SS, Davids JS. Surgical Evaluation and Management of Constipation. Diseases of the colon rectum. 2019;62(6):661–4.

5. Pfeifer J. Surgical options to treat constipation: A brief overview. Rozhledy v chirurgii: mesicnik Ceskoslovenske chirurgicke spolecnosti. 2015;94(9):349–61.

6. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature genetics. 2019;51(4):600–5.

7. Hesson LB, Ng B, Zarzour P, et al. Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Molecular cancer research: MCR. 2016;14(12):1217–28.

8. Jin L, Li L, Hu C, et al. Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory Bowel Disease Colon Biopsies. Inflammatory bowel diseases. 2019.

9. Chen YY, Wen SY, Deng CM, et al. Proteomic Analysis Reveals that Odoroside A Triggers G2/M Arrest and Apoptosis in Colorectal Carcinoma Through ROS-p53 Pathway. Proteomics. 2019;19(15):e1900092.

10. Ly T, Endo A, Brenes A, et al. Proteome-wide analysis of protein abundance and turnover remodelling during oncogenic transformation of human breast epithelial cells. Wellcome open research. 2018;3:51.

11. Kohli M, Oberg AL, Mahoney DW, et al. Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. Clinical genitourinary cancer. 2019;17(4):248–53 e247.
12. Zhao C, Wang F, Wang P, Ding H, Huang X, Shi Z. Early second-trimester plasma protein profiling using multiplexed isobaric tandem mass tag (TMT) labeling predicts gestational diabetes mellitus. Acta diabetologica. 2015;52(6):1103-12.

13. Gao W, Xu J, Wang F, et al. Plasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer. BMC cancer. 2015;15:367.

14. Li N, Tian H, Ma C, et al. [Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2017;20(1):40-6.

15. Equit M, Niemczyk J, Kluth A, Thomas C, Rubly M, von Gontard A. Central Nervous System Processing of Emotions in Children with Fecal Incontinence and Constipation. Zeitschrift fur Kinder- Jugendpsychiatrie Psychotherapie. 2019;47(1):67-71.

16. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–61.

17. Jiang Y, Tang YR, Xie C, Yu T, Xiong WJ, Lin L. Influence of sleep disorders on somatic symptoms, mental health, and quality of life in patients with chronic constipation. Medicine. 2017;96(7):e6093.

18. Hosseinzadeh ST, Poorsaadati S, Radkani B, Forootan M. Psychological disorders in patients with chronic constipation. Gastroenterology hepatology from bed to bench. 2011;4(3):159-63.

19. Askarpour S, Peyvasteh M, Imanipour MH, Javaherizadeh H, Hesam S. Complications after Transabdominal Soave's Procedure in Children with Hirschsprung's Disease. Arquivos brasileiros de cirurgia digestiva: ABCD = Brazilian archives of digestive surgery. 2019;32(1):e1421.

20. Magallon-Tapia M, Ceniceros RA, Arenas-Osuna J, Juarez-Leal CL, Peralta-Amaro AL.
Frequency, clinical evolution and prognosis of toxic megacolon. Revista medica del Instituto Mexicano del Seguro Social. 2015;53(Suppl 1):88–93.

21. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, Lee CR. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug metabolism disposition: the biological fate of chemicals. 2011;39(1):22–9.

22. Morgan ET, Li-Masters T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology. 2002;181–182:207–10.

23. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug metabolism disposition: the biological fate of chemicals. 2008;36(2):205–16.

24. Riddick DS, Lee C, Bhathena A, et al. Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug metabolism disposition: the biological fate of chemicals. 2004;32(4):367–75.

25. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clinical pharmacology therapeutics. 2017;102(4):688–700.

26. Nair PC, McKinnon RA, Miners JO. Cytochrome P450 structure-function: insights from molecular dynamics simulations. Drug metabolism reviews. 2016;48(3):434–52.

27. Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current drug targets. 2018;19(1):38–54.

28. Li L, Shi L, Yang S, et al. SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. Nature communications. 2016;7:12235.

29. Du Y, Cai T, Li T, et al. Lysine malonylation is elevated in type 2 diabetic mouse models and enriched in metabolic associated proteins. Molecular cellular proteomics:
30. Song L, Wang G, Malhotra A, Deutscher MP, Liang W. Reversible acetylation on Lys501 regulates the activity of RNase II. Nucleic Acids Research. 2016;44(5):1979-88.

Figures

A.

B.

Figure 1

Subcellular localization distribution of up-regulated (A) and down-regulated (B) proteins.

A.
### Cellular Component

| Component                       | -log10(p value) |
|--------------------------------|-----------------|
| organellar small ribosomal subunit | 2               |
| mitochondrial small ribosomal subunit | 2               |
| caveola                          | 1.61            |
| plasma membrane raft             | 1.45            |

### Molecular Function

| Activity                                      | -log10(p value) |
|-----------------------------------------------|-----------------|
| lyase activity                               | 3.37            |
| carbonate dehydratase activity               | 3.09            |
| peroxidase activity                          | 2.94            |
| oxidoreductase activity, acting on peroxide...| 2.89            |
| hydro-lyase activity                          | 2.73            |
| carbon-oxygen lyase activity                 | 2.58            |
| glutathione transferase activity             | 2.26            |
| glutathione peroxidase activity              | 2.2             |

### Biological Process

| Process                                      | -log10(p value) |
|----------------------------------------------|-----------------|
| glucose 1-phosphate metabolic process        | 4.24            |
| response to toxic substance                  | 3.01            |
| cellular carbohydrate metabolic process      | 2.65            |
| single-organism biosynthetic process         | 2.52            |
| single-organism metabolic process            | 2.5             |
| carbohydrate derivative biosynthetic process| 2.32            |
| nucleotide-sugar biosynthetic process        | 2.3             |
| bicarbonate transport                         | 2.3             |
| glutathione derivative metabolic process     | 2.19            |
| glutathione derivative biosynthetic process  | 2.19            |
| cellular oxidant detoxification              | 2.09            |
| one-carbon metabolic process                 | 2.08            |
| organic anion transport                       | 2.07            |
| cellular detoxification                      | 2.05            |

### B.

### Cellular Component

| Component                  | -log10(p value) |
|----------------------------|-----------------|
| proteinaceous extracellular matrix | 5.36    |
| extracellular matrix       | 4.9             |
| fibrillar collagen trimer  | 3.75            |
| banded collagen fibril     | 3.75            |
| complex of collagen trimers| 3.43            |
| extracellular space        | 3               |
| collagen trimer            | 2.26            |
| extracellular matrix component | 1.62    |

### Molecular Function

| Function                           | -log10(p value) |
|------------------------------------|-----------------|
| extracellular matrix structural constituent | 3.59    |
| platelet-derived growth factor binding | 3.26    |
| growth factor binding              | 3.13            |
| cytokine binding                   | 2.53            |
Figure 2

GO enrichment results of up-regulated protein (A) and down-regulated protein (B). The horizontal axis value is the negative logarithmic transformation of the significant P value (P < 0.05).
Figure 3
visualization of a KEGG pathway with significant enrichment of differentially expressed proteins. The red color indicates the up-regulated protein and bright green for down-regulated protein.
Figure 4

KEGG pathway enrichment of up-regulated protein (A) and down-regulated protein (B). The horizontal axis value is the negative logarithmic transformation of the significant p value (p <0.05).
Figure 5

heatmap of clustering analysis based on GO enrichment. The three GO categories include Biological Process (A), Cellular Component (B) and Molecular Function (C).

A. KEGG Pathway

- Metabolism of xenobiotics by cytochrome P450
- Amino sugar and nucleotide sugar metabolism
- Chemical carcinogenesis
- Platinum drug resistance
- Glutathione metabolism
- Drug metabolism – other enzymes
- Galactose metabolism
- Drug metabolism – cytochrome P450
- Nitrogen metabolism
- AGE-RAGE signaling pathway in diabetic complications
- Amoebiasis
- Relaxin signaling pathway
- Platelet activation
B. Protein domain

Figure 6

heatmap of clustering analysis based on KEGG pathway (A) and protein domain (B).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

MS_identified_information.xlsx